Introduction {#Sec1}
============

Myeloid differentiation primary response gene (MYD88) is an adaptor protein that activates the nuclear transcription factor κB (NF-κB) signaling through most of the Toll-like receptors (TLRs)^[@CR1]^. An L265P mutation, a change from leucine (CTC) to proline (CCG), in the MYD88 Toll/interleukin (IL)-1 receptor domain, recruits MYD88 protien to the cytoplasmic tail of TLRs to form an active complex. The complex promotes NF-κB and Janus kinase-signal transducer and activator of transcription 3 (JAK-STAT3) signaling^[@CR1]^.

Recently, many investigators have reported that the prevalence of *MYD88* L265P mutation ranges from 0% to 94% in different series of diffuse large B-cell lymphoma (DLBCL) patients^[@CR2]--[@CR41]^. However, since the *MYD88* L265P mutation occurs at various frequencies of DLBCL, a general consensus on clinicopathologic implications has not been reached. DLBCL is a heterogeneous non-Hodgkin's lymphoma mainly comprising molecular subtypes such as germinal center B-cell-like (GCB) and activated B-cell-like (ABC) types^[@CR42]^. Several studies have suggested that the frequency of *MYD88* L265P mutation may vary depending on the tumor site or molecular subtype of DLBCL^[@CR2],\ [@CR8],\ [@CR21],\ [@CR24],\ [@CR30],\ [@CR41]^, but individual studies with different designs hinder clear conclusions. Furthermore, the clinicopathologic significance of the *MYD88* L265P mutation in each DLBCL patient was controversial.

To address these controversies, we conducted a meta-analysis to examine the frequency of *MYD88* L265P mutation and the relationship between this mutation and the clinicopathologic parameters of DLBCL patients.

Results {#Sec2}
=======

Prevalence of *MYD88* L265P mutation in diffuse large B-cell lymphoma {#Sec3}
---------------------------------------------------------------------

On pooled analysis of 40 studies, including 2736 DLBCL patients, the overall prevalence rate of *MYD88* L265P mutation was 29.0% \[95% confidence interval (CI): 17.2--44.5%\] (Table [1](#Tab1){ref-type="table"})^[@CR2]--[@CR41]^. Twenty-nine studies have reported that the frequency of *MYD88* L265P mutation in 2285 DLBCL patients except for central nervous system (CNS) and testicular lymphomas was 16.5% (95% CI: 11.9--22.6%)^[@CR2],\ [@CR3],\ [@CR6],\ [@CR7],\ [@CR9]--[@CR11],\ [@CR13],\ [@CR16]--[@CR22],\ [@CR24],\ [@CR25],\ [@CR27],\ [@CR28],\ [@CR30],\ [@CR31],\ [@CR33]--[@CR39],\ [@CR41]^. Thirteen^[@CR4],\ [@CR5],\ [@CR8],\ [@CR9],\ [@CR12],\ [@CR14],\ [@CR15],\ [@CR18],\ [@CR21],\ [@CR23],\ [@CR26],\ [@CR32],\ [@CR40]^ and four^[@CR8],\ [@CR9],\ [@CR21],\ [@CR29]^ studies reported the prevalence of *MYD88* L265P mutation in 378 CNS and 88 testicular DLBCL patients. The *MYD88* L265P mutation in the CNS and testis were detected in 59.8% (95% CI: 42.2--75.2%) and 77.1% (95% CI: 67.1--84.7%), respectively. The prevalence of *MYD88* L265P mutation in CNS and testicular DLBCL was significantly higher than that of DLBCL in other sites (p \< 0.001, Q = 49.671, *I* ^*2*^ = 95.974). As a result of subgroup analysis, the prevalence of *MYD88* L265P mutation in DLBCL patients was not significantly different according to the race (Supplementary Table [S1](#MOESM1){ref-type="media"}).Table 1Characteristics of individual studies of *MYD88* L265P mutation in diffuse large B-cell lymphoma patients.StudyCountryEthnicityMethodLocationL265P mutation (%)Bohers EFranceCaucasianSeqLN18/161 (11%)Bonzheim IGermany, UKCaucasianSeqVitreoretinal19/28 (68%)Braggio EUSACaucasianExomeSeqCNS9/14 (64%)Bruno AFranceCaucasianExomeSeq, SeqCNS14/37 (38%)Caner VTurkeyAsianSeqLN8/43 (19%)Cani AKUSACaucasianExomeSeqOrbital, ocular3/7 (43%)Chapuy BUSA, Germany, NetherlandsCaucasianExomeSeq, SeqCNS, testes71/104 (68%)Choi JWKoreaAsianSeqLN, CNS, testes8/124 (6%)Cox MCItalyCaucasianAS-PCRLN0/17 (0%)Fernandez-Rodriguez CSpainCaucasianAS-PCRLN17/175 (10%)Fukumura KJapanAsianExomeSeq, SeqCNS35/41 (85%)Gebauer NGermanyCaucasianSeqEBV associated0/26 (0%)Gonzalez-Aguilar AFranceCaucasianExomeSeq, SeqCNS11/29 (38%)Hattori KJapanAsianTargeted SeqCNS28/42 (67%)Jimenez CSpainCaucasianAS-PCRLN9/89 (10%)Juskevicius DSwitzerlandCaucasianTargeted SeqLN7/39 (18%)Kim YKoreaAsianSeqLN, CNS31/161 (19%)Knief JGermanyCaucasianSeqThyroid0/21 (0%)Koens LNetherlandsCaucasianAS-PCR, SeqSkin4/10 (40%)Kraan WNetherlandsCaucasianAS-PCR, SeqLN, CNS, testes38/177 (21%)Lohr JGUSACaucasianExomeSeqLN3/49 (6%)Montesinos-Rongen MGermanyCaucasianSeqCNS5/14 (36%)Morin RDCanadaCaucasianRNA SeqLN6/96 (6%)Nagakita KJapanAsianSeqGastrointestinal3/49 (6%)Nakamura TJapanAsianSeqCNS50/71 (70%)Ngo VNUSACaucasianSeqLN56/242 (23%)Ogura GJapanAsianSeqLN3/8 (38%)Oishi NJapanAsianAS-PCR, Seqtestes18/22 (82%)Pasqualucci LUSACaucasianExomeSeq, SeqLN8/111 (7%)Pham-Ledard AFranceCaucasianAS-PCR, SeqSkin34/58 (59%)Poulain SSpainCaucasianAS-PCR, SeqCNS12/23 (52%)Raja HUSACaucasianAS-PCRVitroretinal14/17 (82%)Rovira JSpainCaucasianAS-PCR, SeqLN39/213 (18%)Santos Gda CCanadaCaucasianSeqLN1/21 (5%)Staiger AMGermanyCaucasianAS-PCRLN13/119 (11%)Taniguchi KJapanAsianAS-PCR, SeqBreast16/28 (57%)Wang CZChinaAsianHRMA, SeqLN11/120 (9%)Xue DChinaAsianHRMA, SeqLN4/42 (10%)Yamada SJapanAsianSeqCNS17/18 (94%)Zhang JUSACaucasianExomeSeqLN9/73 (12%)Seq; sequencing, AS-PCR; allele-specific polymerase chain reaction, HRMA; high resolution melting analysis, LN; lymph node, CNS; central nervous system, EBV; Epstein-Barr virus.

Relationship between *MYD88* L265P mutation and clinical parameters of DLBCL {#Sec4}
----------------------------------------------------------------------------

In this study, we analyzed the relationship between *MYD88* L265P mutation and the clinical features of DLBCL patients except for CNS DLBCL and primary cutaneous DLBCL, leg type, because these two subtypes are clinically different from other DLBCL patients.

Seven studies have described the association of *MYD88* L265P mutation with age^[@CR9],\ [@CR11],\ [@CR17],\ [@CR18],\ [@CR33],\ [@CR34],\ [@CR37]^. The *MYD88* L265P mutation was detected in 96 (21%) of 452 patients of more than 60 years and in 43 (13%) of 320 patients of 60 years or less. The *MYD88* L265P mutation was significantly related to older age (odds ratio (OR) = 1.768; 95% CI: 1.168--2.677; p = 0.007, Q = 3.918, *I* ^*2*^ = 0.000) (Fig. [1](#Fig1){ref-type="fig"}).Figure 1Odds ratios (ORs) with corresponding 95% confidence intervals (CIs) of individual studies and pooled data for the association between *MYD88* L265P mutation and old age. The forest plot demonstrates each study and overall effect sizes and 95% CIs.

Six studies presented the association between *MYD88* L265P mutation and patient's sex^[@CR9],\ [@CR11],\ [@CR17],\ [@CR18],\ [@CR33],\ [@CR34]^. The *MYD88* L265P mutation was found in 69 (17%) of 411 male and in 35 (11%) of 315 female patients. No association was found between the *MYD88* L265P mutation and sex (OR = 1.566; 95% CI: 0.996--2.464; p = 0.052, Q = 4.288, *I* ^*2*^ = 0.000).

Eighteen studies reported that *MYD88* L265P mutation was detected in 255 (21%) of 1236 activated B-cell-like (ABC) or non-germinal center B-cell-like (non-GCB) subtype and in 44 (6%) of 766 GCB subtype patients^[@CR2],\ [@CR6],\ [@CR7],\ [@CR9],\ [@CR11],\ [@CR16],\ [@CR18],\ [@CR21],\ [@CR24],\ [@CR25],\ [@CR27],\ [@CR30],\ [@CR34],\ [@CR36]--[@CR39],\ [@CR41]^. The *MYD88* L265P mutation was significantly associated with ABC or non-GCB subtype (OR = 3.414; 95% CI: 2.243--5.195; p \< 0.001, Q = 19.986, *I* ^*2*^ = 14.865) (Fig. [2](#Fig2){ref-type="fig"}).Figure 2Pooled estimates of the association between *MYD88* L265P mutation and activated B-cell-like (ABC) or non-germinal center B-cell-like (non-GCB) subtype of diffuse large B-cell lymphoma. The forest plot demonstrates each study and overall effect sizes and 95% CIs.

Six studies addressed the relationship between *MYD88* L265P mutation and clinical stage (III, IV versus I, II)^[@CR9],\ [@CR11],\ [@CR17],\ [@CR18],\ [@CR34],\ [@CR37]^. The *MYD88* L265P mutation was detected in 59 (18%) of 336 high-stage and in 101 (22%) of 465 low-stage cases. There was no association between the *MYD88* L265P mutation and clinical stage (OR = 1.244; 95% CI: 0.804--1.924; p = 0.327, Q = 2.377, *I* ^*2*^ = 0.000).

Four studies described the association between *MYD88* L265P mutation and international prognostic index (IPI) risk group^[@CR9],\ [@CR11],\ [@CR18],\ [@CR34]^. The *MYD88* L265P mutation was found in 39 (17%) of 233 cases with the high-risk group and in 54 (13%) of 427 cases with the low-risk group. No relationship was seen between the *MYD88* L265P mutation and IPI risk group (OR = 1.522; 95% CI: 0.939--2446; p = 0.088; Q = 2.883, *I* ^*2*^ = 0.000). However, sensitivity analysis revealed that Kim *et al*.^[@CR18]^ study affected the pooled OR. Therefore, in the case of excluding the study by Kim *et al*.^[@CR18]^, the *MYD88* L265P mutation was significantly related to high IPI risk group (OR = 1.828; 95% CI: 1.061--3.147; p = 0.030).

Survival analysis {#Sec5}
-----------------

Four studies showed accurate multivariate hazard ratios (HRs) and CIs in 436 DLBCL patients including CNS DLBCL cases (Table [2](#Tab2){ref-type="table"})^[@CR11],\ [@CR15],\ [@CR18],\ [@CR31]^. In this meta-analysis, the estimated adjusted HRs ranged from 0.57 to 3.448. No association was found between the *MYD88* L265P mutation and overall survival outcomes (HR = 2.029; 95% CI: 0.873--4.713; p = 0.100, Q = 10.389, *I* ^*2*^ = 71.125).Table 2Hazard ratios and covariates used in the multivariate survival model.StudyCase (No.)HR (95% CI)VariablesFernandez-Rodriguez C1753.448 (1.583--7.509)*MYD88* L265P mutation,\* Hans' phenotype, extranodal site, IPI\*Hattori K422.903 (1.013--8.323)*MYD88* L265P mutation,\* age, altered mental activity,\* CrCl, deep brain involvementKim Y1610.57 (0.23--1.41)*MYD88* L265P mutation, age, IPI,\* *CD79B* mutation, GI origin, chemotherapy regimenPham-Ledard A582.94 (1.18--7.30)*MYD88* L265P mutation,\* age, multifocality,\* locationHR; hazard ratio, CI; confidence interval, IPI; international prognostic index, GI; gastrointestinal \*; independent prognostic variables, P \< 0.05, CrCl; creatinine clearance.

However, we reassessed the relationship between *MYD88* L265P mutation and overall survival of DLBCL in detail based on the subgroup and sensitivity analyses. As a first step, the subgroup analysis revealed that the tumor site of origin (CNS vs. non-CNS DLBCL) and ethnicity did not affect the overall survival outcomes in patients with DLBCL (Supplementary Table [S2](#MOESM1){ref-type="media"}). Although the tumor location did not affect the overall survival of DLBCL, we reanalysed the effect of *MYD88* L265P mutation on the overall survival outcomes of 394 DLBCL patients after excluding CNS DLBCL cases^[@CR15]^. Nevertheless, there was no association between the *MYD88* L265P mutation and overall survival outcomes (HR = 1.817; 95% CI: 0.599--5.515; p = 0.292, Q = 9.906, *I* ^*2*^ = 79.810). Finally, the sensitivity analysis showed that Kim *et al*.^[@CR18]^ study influenced the pooled HR (Fig. [3](#Fig3){ref-type="fig"}), so the meta-analysis was performed again except for Kim *et al*.^[@CR18]^ study. This pooling analysis showed that DLBCL patients with the *MYD88* L265P mutation had low overall survival rates (HR = 3.244; 95% CI: 1.784--5.826; p \< 0.001, Q = 0.068, *I* ^*2*^ = 0.000) (Supplementary Fig. [S1](#MOESM1){ref-type="media"}).Figure 3Sensitivity analysis of meta-analysis for the association between *MYD88* L265P mutation and survival outcomes.

Sensitivity analysis and publication bias {#Sec6}
-----------------------------------------

The sensitivity analysis showed that the pooled analyses of age^[@CR18]^, sex^[@CR17],\ [@CR34]^, IPI^[@CR18]^ and survival outcome^[@CR18]^ according to *MYD88* L256P mutation affected the pooled OR and HR, but the other analyses revealed that none of the studies affected the pooled OR with CIs (Fig. [4](#Fig4){ref-type="fig"}).Figure 4Sensitivity analysis of meta-analysis for the association between *MYD88* L265P mutation and ABC or non-GCB subtype of diffuse large B-cell lymphoma. When each study is sequentially removed and meta-analysis is repeated with the remaining studies, the pooled odds ratios (ORs) remain almost the same.

In the funnel plot and Egger regression test, there was no evidence of publication bias except for the meta-analysis for the association of *MYD88* L265P mutation with the DLBCL subtypes (Supplementary Table [S3](#MOESM1){ref-type="media"}) (Fig. [5](#Fig5){ref-type="fig"}).Figure 5Funnel plot of meta-analysis for the association between *MYD88* L265P mutation and age. Individual studies, indicated by small circles, are uniformly distributed in inverted V-shape and indicate no published bias.

Discussion {#Sec7}
==========

This pooled analysis showed that the tumor location of origin in DLBCL contributes to the prevalence difference of *MYD88* L265P mutation. Moreover, the *MYD88* L265P mutation is found in the ABC or non-GCB subtype more frequently than the GCB subtype of DLBCL.

We found that the incidence of *MYD88* L265P mutation in DLBCL patients varies from tumor site to tumor site. CNS and testicular DLBCLs are present as extra-nodal localized masses and show inferior responses to current chemotherapy regimens^[@CR8]^. Interestingly, Kraan *et al*. suggested that the *MYD88* L265P mutation in DLBCL is associated with an immune-privileged anatomical compartment, such as the CNS or the testis^[@CR21]^. Consistent with the previous result, this study showed that the *MYD88* L265P mutation is most common in DLBCL at immunologically privileged sites.

This pooled analysis revealed that the *MYD88* L265P mutation in DLBCL is significantly associated with the ABC or non-GCB subtype. ABC type DLBCL is characterized by chronic active B-cell receptor signaling and intrinsic activation of the NF-κB pathway, which can contribute to poor response to chemotherapy^[@CR43]^. Initially, Ngo *et al*. claimed that GCB subtype has almost no *MYD88* L265P mutation^[@CR27]^. Since then, some studies have reported that the *MYD88* L265P mutation occurs at a significantly higher frequency in ABC or non-GCB subtypes^[@CR2],\ [@CR21],\ [@CR24],\ [@CR30],\ [@CR41]^. In contrast, other studies did not show a significant association between the *MYD88* L265P mutation and the DLBCL molecular subtypes^[@CR16],\ [@CR18],\ [@CR38]^.

The prognostic value of the *MYD88* L265P mutation has been the matter of controversy. Some studies have reported that *MYD88* L265P mutation is significantly associated with low survival rates^[@CR11],\ [@CR15],\ [@CR31],\ [@CR34]^. However, we did not reach a clear conclusion through the initial pooled analysis. Except for individual studies found not to be suitable for meta-analysis by sensitivity analysis, a second pool analysis revealed that the *MYD88* L265P mutation was associated with a low survival rate and a high IPI risk group. Our results indicate that the *MYD88* L265P mutation is significantly associated with patients older than 60 years, but not with gender and clinical stage. More studies are needed to demonstrate the negative prognostic effect of the *MYD88* L265P mutation in DLBCL patients.

Some studies have mentioned other *MYD88* mutations, such as S243N and S219C other than L265P^[@CR2],\ [@CR7],\ [@CR21],\ [@CR24],\ [@CR27],\ [@CR30],\ [@CR34]^. In particular, Rovira *et al*. compared the clinical characteristics between L265P mutation and other *MYD88* mutations^[@CR34]^. However, there was not enough published data to perform a meta-analysis on this issue.

Targeting the MYD88 pathway in patients with DLBCL who do not respond well to anti-CD20 antibody therapy (rituximab) may be an attractive option. Interestingly, ABC type DLBCL with the *MYD88* mutation often responds to Ibrutinib, a selective inhibitor of Bruton tyrosine kinase (BTK)^[@CR44]^. Thus, the *MYD88* mutation status of DLBCL may be a good predictor of chemotherapy in DLBCL patients.

There are several limitations to the current meta-analysis. First, we classified patients as white and Asian, but there may be discrepancies between our classification and the original data. Second, individual studies used different analytical methods and heterogeneous clinical samples. Third, the criteria for determining the molecular subtype of DLBCL differed somewhat between studies. Finally, the meta-analysis for overall survival could not be performed using the survival data from DLBCL patients completely excluding CNS and primary cutaneous DLBCL, leg type. We could not extract the survival HRs and CIs from nodal DLBCL from the published data because the previous studies presented only the survival HRs and CIs of DLBCL cases including some CNS and/or primary cutaneous DLBCLs. These limitations might affect the results of this pooled analysis.

Conclusion {#Sec8}
==========

This meta-analysis indicates that the *MYD88* L265P mutation is a significant mutation in the DLBCL of the immune-privileged region and is significantly associated with the ABC or the non-GCB subtype of DLBCL. This mutation can be a powerful driver of high NF-κB activity, a characteristic of DLBCL's ABC or non-GCB subtypes.

Methods {#Sec9}
=======

Data collection and selection criteria {#Sec10}
--------------------------------------

We searched PubMed (<http://www.ncbi.nlm.nih.gov/pubmed>) and EMBASE ([www.embase.com](http://www.embase.com)) using the keywords "MYD88", "lymphoma", and "whole sequencing". We also manually searched the reference lists of the identified articles. Duplicate data or overlapping articles were excluded by examining the authors' names and affiliations. Original articles reporting cases of *MYD88* L265P mutation published before September 2016 were included. When multiple articles were published by the same authors or institutions, the most recent or single informative article was selected. Articles lacking clinicopathologic data for meta-analysis, review articles without original data, conference abstracts, case reports, and articles that dealt with cell line or animal were excluded. There were no geographic or language restrictions. The selection process of the articles is shown in Fig. [6](#Fig6){ref-type="fig"}.Figure 6Article selection flow chart.

Data pooling and statistics {#Sec11}
---------------------------

Meta-analysis was performed as previously described^[@CR45]^. Briefly, effect sizes for each study were calculated by the prevalence rate and OR or HR and the corresponding 95% CI using the Mantel-Haenszel method or the Cohen method. The prevalence rates or ORs or HRs were combined using the random-effects model (DerSimonian-Laird method). The prevalence rates, ORs, or HRs were combined using the random-effects model (DerSimonian-Laird method). Statistical heterogeneity among studies was evaluated using the Cochrane Q test and *I* ^*2*^ statistics. The *I* ^*2*^ statistic refers to the percentage of variation across studies that is due to heterogeneity rather than chance and does not inherently depend on the number of studies considered \[*I* ^*2*^ = 100% × (Q - df)/Q\]. We clarified the cutoff of *I* ^*2*^ statistics for assignment of low (\<25%), moderate (25--50%), and high (\>50%) heterogeneities. If the *I* ^*2*^ value was more than 25%, subgroup analysis was done. Sensitivity analyses were performed to examine the influence of each study on the pooled prevalence rate and OR or HR by serially omitting an individual study and pooling the remaining studies. Publication bias was examined by funnel plots and Egger's tests for the degree of asymmetry. If the P value is less than 0.1, it is assumed that a publication bias exists. The pooled analysis was performed using Comprehensive Meta-analysis Software version 2.0 (Biostat, Englewood, NJ, USA).
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